Newer diabetes drugs cost more, but may not work better

February 28, 2014 by Nicole Casal Moore, University of Michigan

Two newer classes of drugs to treat adult-onset diabetes may be no more effective than the old standby, yet they cost significantly more over the course of a patient's disease.

That's according to a National Science Foundation-funded study by researchers at the University of Michigan, Mayo Clinic and North Carolina State University.

Based on a simulation model that involved 15 years worth of actual patient data from more than 37,000 individuals, the researchers found that the newer drugs cost patients and insurance companies anywhere from $1,600 to $2,400 more.

That's from the time a person is diagnosed until he or she develops heart problems, circulatory complications or dies. The exact time period varies widely, but it can be more than a decade.

Some 25 million Americans live with today, so the researchers say the findings offer an avenue for substantial savings.

"Conventional wisdom would suggest the newer medications should be more effective since they cost more, but what we find is that they don't appear to result in people living longer or avoiding complications," said principal investigator Brian Denton, U-M associate professor of industrial and operations engineering who specializes in medical decision-making.

The drugs they studied are the second line of defense when the body develops resistance to the gold standard medication known as metformin. At that point, doctors typically prescribe an additional pill to stave off daily insulin shots. While there are many different options, there's no consensus as to which work best.

The , developed by lead study author Yuanhui Zhang, a doctoral student at North Carolina State, compared the newer classes known as DPP-IV inhibitors and GLP-1 agonists with the older drug called sulfonylurea. They all have different mechanisms for stabilizing patients' blood sugar levels (DPP-IV inhibitors are marketed under the names names Januvia, Onglyza and Tradjenta; popular GLP-1 agonists include Byetta and Victoza).

In the years since the more modern drugs have been released, many doctors have shifted to prescribing them over the older sulfonylurea—partially because they don't have the risk of hypoglycemia and weight-gain side effects that sulfonylurea can have. But the shift is partially to blame for a rise in the cost of and management, the study shows.

"All of the medications that have been considered in the model have some risk and down sides that can impact a person's well-being," said Steven Smith, an endocrinologist at Mayo Clinic. "But our model can help to assess optimal decision-making that would take into account individual and unique risks for all medications, old and new."

Down the road, the researchers envision a tool that doctors themselves can use.

Simulations can provide a unique perspective that could in some ways model the real world better than a clinical trial, Denton said. Patients participating in a clinical trial may behave differently than they would otherwise, adhering to doctors' orders better.

Explore further: Linagliptin noninferior to glimepiride in type 2 diabetes

More information: Yuanhui Zhang, Rozalina G. McCoy, Jennifer E. Mason, Steven A. Smith, Nilay D. Shah, and Brian T. Denton. "Second-line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better?" Diabetes Care published ahead of print February 26, 2014, DOI: 10.2337/dc13-1901 1935-5548

Related Stories

Linagliptin noninferior to glimepiride in type 2 diabetes

June 28, 2012
(HealthDay) -- A new drug for type 2 diabetes causes significantly less weight gain and may carry lower risks for hypoglycemia (low blood sugar), heart attack and stroke than standard medications, a new study indicates.

ACP recommends metformin to treat type 2 diabetes based on CE analysis of oral medications

February 6, 2012
The American College of Physicians (ACP) recommends that clinicians add metformin as the initial drug treatment for most patients with type 2 diabetes when lifestyle modifications such as diet, exercise, and weight loss have ...

Diabetes drugs taken by over 15 million Americans raises risk of bladder cancer

August 13, 2012
A popular class of diabetes drugs increases patients' risk of bladder cancer, according to a new study published online this month in the Journal of the National Cancer Institute. Researchers from the Perelman School of Medicine ...

US probes new pancreas risks with diabetes drugs (Update)

March 14, 2013
The U.S. Food and Drug Administration is looking into new evidence that suggests a group of recently approved diabetes drugs can increase the risk of pancreatitis and other problems.

Computer simulation shows that knowing patients' genetic profiles can save money, improve outcomes

February 20, 2014
(Medical Xpress)—Genetic testing can help doctors choose the most effective and economical drugs to prevent blood clots in the half a million patients in the U.S. who receive coronary stents each year, according to a new ...

Recommended for you

New therapeutic avenue for type 2 diabetes

December 6, 2018
Restoring the action of insulin is one of the keys to fighting type 2 diabetes. Researchers from Inserm led by Dominique Langin at the Institute of Cardiovascular and Metabolic Diseases (Inserm/Université de Toulouse) are ...

Subtype of immune B cells can delay type 1 diabetes onset in mice

December 6, 2018
A team of researchers at Baylor College of Medicine and the University of Michigan Medical School reports today in the JCI Insight that a subset of immune B cells, known as CD19+IgM+ B cells, can delay the onset of type 1 ...

Is the pancreas regeneration debate settled? An original theory renewed

December 5, 2018
A contentious debate among diabetes researchers has surrounded the regeneration of pancreatic insulin-producing cells: not if these cells regenerate, but rather how.

One in four patients say they've skimped on insulin because of high cost

December 3, 2018
For patients with diabetes, insulin is a life-saving medicine and an essential component of diabetes management, yet in the past decade alone, the out-of-pocket costs for insulin have doubled in the United States. One-quarter ...

Parsing diabetic skin infections

December 3, 2018
People with diabetes are more susceptible to skin infection. According to a new study by C. Henrique Serezani, Ph.D., Stephanie Brandt, Ph.D., and colleagues, this susceptibility might be due to overabundance of a compound ...

Next step toward replacement therapy in type 1 diabetes

November 28, 2018
Scientists have discovered the signals that determine the fate of immature cells in the pancreas. The research shows that they are very mobile and that their destiny is strongly influenced by their immediate environment. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.